BMYJuno Therapeutics, Inc., a Bristol-Myers Squibb CompanySigning up patients
A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma
Lymphoma
3Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +2.6
2 insiders sold shares within a month
Since Sep 9, 2026 · was worth 5, fading over time
Worry score3
Score over time
- Stage
- Phase 2
- Patients
- 65 (planned)
- Started
- Nov 6, 2025
- Main results expected
- Jan 9, 2028
- Fully finished
- Dec 10, 2028
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Progression-free Survival (PFS)
Measured over: 12 months after liso-cel infusion
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 2.6, since 2026-09-09, fades (half-life)
Raw record changes
- none yet
Trial ID NCT07015242 · record last updated 2026-11-05 · checked 2026-11-09 15:47 UTC